SLC7A11 and neoplasm: Yu et al. (LI et al., 2020b) used cisplatin (CDDP)-resistant non-small cell lung cancer cells (N5CP cells) and found that CDDP-mediated activation of the xCT pathway is related to the resistance of cells to CDDP, while ergot alkaloid or sorafenib can increase the sensitivity of tumour cells to CDDP by inhibiting xCT pathway, and the two combined with low-dose CDDP can more effectively inhibit the growth of N5CP cells.